Nature Reviews Rheumatology

Papers
(The H4-Index of Nature Reviews Rheumatology is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Inflammatory arthritis affects men’s fertility595
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis444
Bimekizumab effective across the axSpA spectrum391
No benefit from adding MTX to ustekinumab344
Low-dose rituximab can go even lower324
Genome-wide mutagenesis reported in systemic sclerosis299
Rheumatic diseases on the rise282
A role for TGFβ and EBV in MIS-C pathogenesis253
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations230
Targeting articular Mmp13 in OA200
Biological and clinical roles of IL-18 in inflammatory diseases191
New drug formulation reduces bone loss182
FOXP3 splice variant is associated with autoimmune disease173
Towards better management of sterile bone inflammation168
Use of platelet-rich plasma for knee OA not supported by RCT results164
MIS-C: myths have been debunked, but mysteries remain163
Inflammation across tissues: can shared cell biology help design smarter trials?151
Which NSAIDs are best for OA treatment?150
Urchin-like nanoparticles for miRNA therapy of OA143
2021 ACR guideline for JIA reflects changes in practice142
The 2022 ACR vaccination guideline: a call-to-action129
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?119
The value of comparative efficacy studies in informing rheumatology guidelines119
To choose or not? The value of discrete-choice experiments in rheumatology117
Down syndrome: insights into autoimmune mechanisms116
Ageing stem cells hold the key to age-related bone degeneration110
Appraising the evolving landscape of protease inhibition in osteoarthritis106
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus103
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician100
Co-trimoxazole reduces mortality in anti-MDA5-DM95
Calprotectin tracks tocilizumab-treated RA93
Low-dose glucocorticoids benefit seniors with RA93
Wnt-induced IGF1 drives OA92
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?92
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician89
Author Correction: Proposals for the rheumatological use of JAK inhibitors88
A direct link between SARS-CoV-2 and bone loss87
Guiding ILD management in systemic autoimmune rheumatic diseases87
S100A4 inhibition targets fibrosis in SSc85
Rheumatic diseases and metabolism: where centre and periphery meet83
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis78
Fumarate drives interferon release in systemic sclerosis monocytes78
Rheumatology in the digital health era: status quo and quo vadis?77
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis76
Low back pain is a growing concern74
sCD13 role in arthritis mediated via bradykinin receptor74
Antibiotics keep rheumatic heart disease at bay73
Targeting the IVD clock to halt degeneration73
Erosive cargo from synovial fibroblasts71
Which DMARD for ICI-associated arthritis?70
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus69
ERAP1 and the return of the UPR in ankylosing spondylitis68
Chimeric receptors broaden the therapeutic landscape for autoimmune disease68
PGE2 receptor antagonist has potential to treat osteoarthritis66
Macrophage-coated nanocarriers for gouty arthritis64
A path towards personalized medicine for autoinflammatory and related diseases64
CAR T cells induce drug-free SLE remission62
Insights into IVDD pathogenesis in 202462
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach61
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative60
0.072953939437866